QuantaMatrix Inc.

QuantaMatrix is a global leader in innovative in-vitro diagnostics, dedicated to addressing urgent and unmet healthcare challenges through faster, more precise diagnostic solutions. Our flagship system, dRAST, is an AI-driven rapid antimicrobial susceptibility testing solution that slashes sepsis diagnostic turnaround time from days to hours, enabling clinicians to initiate timely, targeted antibiotic therapy when it matters most. For advanced multiplex immunoassay testing, we offer QMIA, a fully automated sample-to-answer analyzer designed to streamline and optimize laboratory workflows. Running on the QMIA platform, AlzPlus is an innovative blood-based reagent that evaluates four distinct plasma biomarkers through a proprietary algorithm to assess amyloid-beta pathology, supporting earlier identification of individuals at risk for Alzheimer's disease. Across our product portfolio, QuantaMatrix is committed to delivering diagnostic solutions that are fast, precise, and highly accessible — empowering clinicians and laboratories to act sooner, with greater confidence, for better patient outcomes.

*QuantaMatrix Inc. will soon become QMiCo Inc. as a member of MiCo Group.